maliqun61 schreef op 2 juni 2018 19:28:
Voor wie op de AVA geweest is. Is er nog iets gezegd over de relatie Pharming-Bioconnection? Dit nav opmerking in jaarverslag:
(pag 94)
LONG-TERM PREPAYMENT The Long-term prepayment (€2.3 million as at 31 December 2017) is related to the manufacturing agreement with BioConnection, a contract manufacturing organization, and represents three instalments, of €0.5 million each, plus prepaid batches, made to secure and guarantee sufficient future production capacity. These instalments and prepayments represent prepaid production costs of Drug Product batches. The prepayment will be settled by BioConnection by deductions from the cost of future production of finished goods batches.
Bovendien:
pag 39
Pharming's future supplies of RUCONEST® are dependent on third parties Pharming has entered into (downstream) manufacturing and supply agreements for the production of rhC1INH, the drug substance of RUCONEST®, namely with Sanofi and BioConnection. Pharming may have to develop and/or contract additional (upstream or downstream) manufacturing capabilities and may have to develop or contract additional (downstream) purification capacity. It is uncertain whether and to what extent Pharming will be able to develop such capabilities or enter into such partnerships or agreements on a timely basis and on acceptable terms. Even if a partnership or agreement has been concluded, the possibility exists that these partners fail to live up to the agreements made with them or that Pharming is unable to maintain such agreements. A failure to develop and/or sufficiently contract additional manufacturing capacity on a timely basis could have significant detrimental consequences 40 for Pharming's business, financial position, results of operations, prospects and market price of the shares.